Evaluation of the impact of pharmaceutical care service on hospitalized patients with chronic kidney disease in Jordan
- 25 July 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Clinical Pharmacy
- Vol. 35 (5), 780-789
- https://doi.org/10.1007/s11096-013-9806-8
Abstract
Objectives The primary goal of the present study was to implement and evaluate the impact of pharmaceutical care service for hospitalized chronic kidney disease (CKD) patients in Jordan. Setting Nephrology wards of one of the largest general hospitals in Jordan. Methods All patients who were previously diagnosed with CKD by their physician were eligible for inclusion in the study. Recruited patients were fully assessed for treatment related problems (TRPs) by a clinical pharmacist. Pharmaceutical care service was assessed through a systematic, prospective before–after design. Chi Square test was used to investigate association between categorical variables. P value Main outcome measures Study outcomes included: Process outcomes (prevalence and nature of identified TRPs, clinical significance of TRPs, associated diseases and drugs), General clinical outcomes (Therapeutic outcomes of TRPs) and CKD specific clinical outcomes (Change from baseline in the number of patients receiving appropriate progression modifying therapy and appropriate management of complications). Results 130 patients were included in the study. The average number of the identified TRPs was 5.31. Eighty-six percent of the recommendations were accepted by physicians. Efficacy related problems were the most common TRP category. Seventeen percent of all TRPs were resolved, 5.5 % were improved, and 37.4 % were prevented through the clinical pharmacist interventions. Conclusions The current study indicated that hospitalized patients with CKD suffer from multiple TRPs mostly related to efficacy of medications and patients monitoring. Clinical pharmacists substantially contributed towards the care of hospitalized CKD patients through optimizing progression modifying therapies, medications safety and management of CKD complications. Based on this study it is strongly recommended to implement pharmaceutical care services for hospitalized CKD patients.Keywords
This publication has 21 references indexed in Scilit:
- Development and Validation of the PAIR (Pharmacotherapy Assessment in Chronic Renal Disease) Criteria to Assess Medication Safety and Use Issues in Patients With CKDAmerican Journal of Kidney Diseases, 2011
- Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature reviewBMC Nephrology, 2011
- Burden of Chronic Kidney Disease: An International PerspectiveAdvances in Chronic Kidney Disease, 2010
- Estimating glomerular filtration rate with a modification of diet in renal disease equation: Implications for pharmacyAmerican Journal of Health-System Pharmacy, 2007
- Prevention programmes of progressive renal disease in developing nations (Review Article)Nephrology, 2006
- The Case for Disease Management in Chronic Kidney DiseaseDisease Management, 2006
- Executing Change in the Management of Chronic Kidney Disease: Perspectives on Guidelines and PracticeMedical Clinics of North America, 2005
- Anemia and End‐Stage Renal Disease in the Developing WorldArtificial Organs, 2002
- Chronic kidney disease: why is current management uncoordinated and suboptimal?Nephrology Dialysis Transplantation, 2001
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976